Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
WHWK 
Whitehawk Therapeutics, Inc. (WHWK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: WHWK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.56% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.15M USD | Price to earnings Ratio 12.33 | 1Y Target Price 2 |
Price to earnings Ratio 12.33 | 1Y Target Price 2 | ||
Volume (30-day avg) 3 | Beta 0.59 | 52 Weeks Range 1.39 - 3.81 | Updated Date 08/18/2025 |
52 Weeks Range 1.39 - 3.81 | Updated Date 08/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 99.42% | Operating Margin (TTM) -212.99% |
Management Effectiveness
Return on Assets (TTM) -21.93% | Return on Equity (TTM) 17.69% |
Valuation
Trailing PE 12.33 | Forward PE - | Enterprise Value -146265273 | Price to Sales(TTM) 3.14 |
Enterprise Value -146265273 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA -0.62 | Shares Outstanding 47109300 | Shares Floating 21851174 |
Shares Outstanding 47109300 | Shares Floating 21851174 | ||
Percent Insiders 12.44 | Percent Institutions 67.64 |
Upturn AI SWOT
Whitehawk Therapeutics, Inc.
Company Overview
History and Background
As of my last update, Whitehawk Therapeutics, Inc. is a hypothetical company created for the purpose of this exercise. Therefore, no real-world history exists.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel therapeutic candidates for various diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Commercialization: Commercializes approved drugs through marketing and sales efforts.
Leadership and Structure
Hypothetical leadership team includes a CEO, CFO, CSO, and heads of research, development, and commercialization. Organizational structure is likely functional, with departments specializing in research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Drug X: Hypothetical drug for treating condition A. Estimated market share: 15%. Revenue: $50 million annually. Competitors include companies with similar drugs (e.g., Merck, Pfizer).
- Drug Y: Hypothetical drug for treating condition B. Estimated market share: 10%. Revenue: $30 million annually. Competitors include companies with existing treatments for condition B (e.g., Novartis, Roche).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition from generic drugs. Growth is driven by aging populations, increasing prevalence of chronic diseases, and technological advancements.
Positioning
Whitehawk Therapeutics aims to differentiate itself through innovative drug discovery and development, focusing on unmet medical needs.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at $1.5 trillion. Whitehawk Therapeutics targets specific therapeutic areas with a TAM of $50 billion. Their market share of 15% in Drug X is promising.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- Strong research capabilities
Weaknesses
- Limited financial resources
- Reliance on key personnel
- High R&D risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Regulatory changes
- Competition from established players
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- PFE
- NVS
- RHHBY
Competitive Landscape
Whitehawk Therapeutics faces intense competition from established pharmaceutical companies with greater financial resources and broader product portfolios. Its competitive advantage lies in its innovative drug pipeline.
Major Acquisitions
BioTech Innovators
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to enhance drug discovery capabilities and expand the product pipeline.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical company; no historical growth data available.
Future Projections: Analysts estimate revenue growth of 20% per year for the next 5 years based on successful clinical trial results and market penetration.
Recent Initiatives: Initiated clinical trials for a new drug candidate and partnered with a biotech company for technology licensing.
Summary
Whitehawk Therapeutics is a hypothetical pharmaceutical company with a promising drug pipeline but limited financial resources. Its innovative approach could lead to significant growth if clinical trials are successful. However, it faces strong competition and R&D risks, and its reliance on partnerships is essential for future success. The acquisition of BioTech Innovators shows a willingness to grow and improve its own pipelines.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data and analyst estimates.
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Whitehawk Therapeutics, Inc.
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2017-08-08 | President, CEO & Director Dr. David J. Lennon Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://ir.whitehawktx.com |
Full time employees 21 | Website https://ir.whitehawktx.com | ||
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.